Immune Cells Produce Natural Painkillers Right at the Site of Inflammation

Dynorphin was found in both immune cells and sensory nerve fibers within inflamed rat tissue, showing the body deploys its own pain relief locally.

Hassan, A H et al.·Neuroscience letters·1992·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-00236Animal StudyPreliminary Evidence1992RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Dynorphin immunoreactivity detected in both inflammatory cells and cutaneous sensory nerve fibers in Freund's adjuvant-inflamed rat paw tissue.

Key Numbers

How They Did This

Immunohistochemistry for dynorphin and calcitonin gene-related peptide (CGRP, a sensory nerve marker) on tissue sections from inflamed and normal rat hindpaws.

Why This Research Matters

This shows the body has a local pain-relief system at inflammation sites. Immune cells produce dynorphin right where it is needed, which could be enhanced for better pain treatment.

The Bigger Picture

The immune system doesn't just fight infection — it also produces natural painkillers at injury sites. Understanding this local opioid production could lead to targeted pain treatments that work at the inflammation site without brain-level side effects.

What This Study Doesn't Tell Us

Animal study in rats with a chemical inflammation model. Immunohistochemistry shows presence but not release or activity. Cannot quantify how much dynorphin the immune cells produce.

Questions This Raises

  • ?Can we enhance immune cell dynorphin production to improve natural pain relief?
  • ?Is this local opioid system impaired in chronic pain conditions?

Trust & Context

Key Stat:
Dual source Dynorphin found in both immune cells AND sensory nerves at inflammation sites — two local sources of natural pain relief
Evidence Grade:
Preliminary — immunohistochemical study showing dynorphin presence but not confirming its release or functional pain-relieving activity at the site.
Study Age:
Published in 1992 (34 years ago). Peripheral opioid analgesia has since become an active research area with clinical applications.
Original Title:
Dynorphin, a preferential ligand for kappa-opioid receptors, is present in nerve fibers and immune cells within inflamed tissue of the rat.
Published In:
Neuroscience letters, 140(1), 85-8 (1992)
Database ID:
RPEP-00236

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Why would immune cells produce opioid painkillers?

It appears to be a coordinated defense response — immune cells rush to injury sites to fight infection, and some also produce dynorphin to reduce pain locally. This helps the body manage inflammation without relying solely on brain-based pain control.

Could this lead to better pain treatments?

Yes — if we can boost the immune system's local opioid production or mimic it with drugs that only work at inflammation sites, we could treat pain without the addiction and sedation caused by brain-acting opioids.

Read More on RethinkPeptides

Cite This Study

RPEP-00236·https://rethinkpeptides.com/research/RPEP-00236

APA

Hassan, A H; Pzewłocki, R; Herz, A; Stein, C. (1992). Dynorphin, a preferential ligand for kappa-opioid receptors, is present in nerve fibers and immune cells within inflamed tissue of the rat.. Neuroscience letters, 140(1), 85-8.

MLA

Hassan, A H, et al. "Dynorphin, a preferential ligand for kappa-opioid receptors, is present in nerve fibers and immune cells within inflamed tissue of the rat.." Neuroscience letters, 1992.

RethinkPeptides

RethinkPeptides Research Database. "Dynorphin, a preferential ligand for kappa-opioid receptors,..." RPEP-00236. Retrieved from https://rethinkpeptides.com/research/hassan-1992-dynorphin-a-preferential-ligand

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.